synthetic adeno-associated viral vector-based ASAH1 gene therapy (Gromit Therapeutics/Icahn School of Medicine/Hebrew University of Jerusalem)

N/A

报告时间: 2025/01/26 15:53:58

基本信息

药物名称synthetic adeno-associated viral vector-based ASAH1 gene therapy (Gromit Therapeutics/Icahn School of Medicine/Hebrew University of Jerusalem)

药物别称ASAH1 gene therapy (Gromit Therapeutics/Icahn School of Medicine/Hebrew University of Jerusalem)Anc80L65 vector-based ASAH1 gene therapy (Gromit Therapeutics/Icahn School of Medicine/Hebrew University of Jerusalem)

药物类型生物药

作用机制酸性神经酰胺酶刺激剂

靶点酸性神经酰胺酶

治疗领域 / 适应症肺性高血压

全球批准适应症N/A

中国批准适应症N/A

首批国家/区域N/A

首批日期N/A

国家/区域美国以色列

是否复方否

全球最高研发状态临床前

中国最高研发状态N/A

原研公司Icahn School Of Medicine At Mount Sinai

注册分类N/A

研发信息

活跃公司Gromit Therapeutics Inc Icahn School Of Medicine At Mount Sinai The Hebrew University Of Jerusalem

非活跃公司N/A

活跃适应症肺性高血压

非活跃适应症N/A

其他信息

ATC代码N/A